Cases / 2023-R-001
completed2023-02-09R series

Dalbavancin

Open official case page ↗
Brand
Xydalba
Manufacturer
Advanz Pharma Germany GmbH

G-BA action

exemption

2023-04-20

Antrag auf Freistellung von der Verpflichtung zur Vorlage der Nachweise nach § 35a Abs. 1 Satz 3 Nr. 2 und 3 SGB V wegen des Status als Reserveantibiotikum: Dalbavancin

Evidence-checked summary

The G-BA issued a exemption on 2023-04-20. The official page states that it took effect as follows: mit Beschlussdatum. The page lists Arzneimittel-Richtlinie as the normative target.

This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.

Official case record

What happened, in source order

No inferred stages

Consultation record

Oral hearing and Wortprotokoll

0 hearing

No official oral hearing is attached to this case.

IQWiG comparison

Assessment record versus G-BA action

0 reference

IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.

No IQWiG assessment reference is present on the validated official case page. This is an explicit absence, not a broken graph link.

G-BA decisions

Distinct actions and documents

1 decision

2023-04-20

exemption

Antrag auf Freistellung von der Verpflichtung zur Vorlage der Nachweise nach § 35a Abs. 1 Satz 3 Nr. 2 und 3 SGB V wegen des Status als Reserveantibiotikum: Dalbavancin

The G-BA issued a exemption on 2023-04-20. The official page states that it took effect as follows: mit Beschlussdatum. The page lists Arzneimittel-Richtlinie as the normative target.

2 official documents · 3 cited claims

Official sources

Case document package

3 source
Generic graph relations · 1